ORAGENICS, INC. Restricted Stock or Unit Expense
ORAGENICS, INC. (OGEN) reported Restricted Stock or Unit Expense of $5.05 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RestrictedStockExpense · last filed 2025-03-14
- ORAGENICS, INC. restricted stock or unit expense for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- ORAGENICS, INC. restricted stock or unit expense for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- ORAGENICS, INC. restricted stock or unit expense for the quarter ending 2017-12-31 was $8.62K, a 87.17% decline year-over-year.
- ORAGENICS, INC. restricted stock or unit expense for the quarter ending 2017-09-30 was $20.75K.
- ORAGENICS, INC. restricted stock or unit expense for fiscal 2024 was $5.05K, a 98.92% decline from fiscal 2023.
- ORAGENICS, INC. restricted stock or unit expense for fiscal 2023 was $466.75K.
- ORAGENICS, INC. restricted stock or unit expense for fiscal 2022 was $0.00.
- ORAGENICS, INC. restricted stock or unit expense for fiscal 2018 was $24.32K, a 80.26% decline from fiscal 2017.
| Period end | Restricted Stock or Unit Expense 3 month | Restricted Stock or Unit Expense 6 month | Restricted Stock or Unit Expense 9 month | Restricted Stock or Unit Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | $5.05K 10-K · filed 2025-03-14 | |||
| 2023-12-31 | $466.75K 10-K · filed 2024-03-29 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-29 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $0.00 derived: sum of 2 quarters · filed 2019-03-29 | $24.32K 10-K · filed 2019-03-29 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $24.32K 10-Q · filed 2018-11-13 | ||
| 2018-06-30 | $24.32K 10-Q · filed 2019-08-14 | |||
| 2017-12-31 | $8.62K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $29.37K derived: sum of 2 quarters · filed 2019-03-29 | $69.68K derived: sum of 3 quarters · filed 2019-03-29 | $123.20K 10-K · filed 2019-03-29 |
| 2017-09-30 | $20.75K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $61.06K derived: sum of 2 quarters · filed 2018-11-13 | $114.58K 10-Q · filed 2018-11-13 | $181.78K derived: sum of 4 quarters · filed 2018-11-13 |
| 2017-06-30 | $40.31K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $93.83K 10-Q · filed 2018-08-13 | $161.03K derived: sum of 3 quarters · filed 2018-08-13 | $161.03K derived: sum of 4 quarters · filed 2018-08-13 |
| 2017-03-31 | $53.52K 10-Q · filed 2018-05-15 | $120.72K derived: sum of 2 quarters · filed 2018-05-15 | $120.72K derived: sum of 3 quarters · filed 2018-05-15 | $162.72K derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | $67.20K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $67.20K derived: sum of 2 quarters · filed 2018-02-16 | $109.20K derived: sum of 3 quarters · filed 2018-02-16 | $151.20K 10-K · filed 2018-02-16 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $42.00K derived: sum of 2 quarters · filed 2017-10-31 | $84.00K 10-Q · filed 2017-10-31 | |
| 2016-06-30 | $42.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $84.00K 10-Q · filed 2017-08-14 | ||
| 2016-03-31 | $42.00K 10-Q · filed 2017-05-15 | |||
| 2015-12-31 | $264.00K 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |